[go: up one dir, main page]

WO2003053352A3 - Therapeutic compounds for treating dyslipidemic conditions - Google Patents

Therapeutic compounds for treating dyslipidemic conditions Download PDF

Info

Publication number
WO2003053352A3
WO2003053352A3 PCT/US2002/040236 US0240236W WO03053352A3 WO 2003053352 A3 WO2003053352 A3 WO 2003053352A3 US 0240236 W US0240236 W US 0240236W WO 03053352 A3 WO03053352 A3 WO 03053352A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic compounds
dyslipidemic conditions
treating dyslipidemic
treating
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/040236
Other languages
French (fr)
Other versions
WO2003053352A2 (en
Inventor
A Brian Jones
Alan D Adams
Bruno Tse
Shaei Y Huang
Ahren Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to JP2003554112A priority Critical patent/JP2005519042A/en
Priority to US10/498,771 priority patent/US20040266849A1/en
Priority to CA002470591A priority patent/CA2470591A1/en
Priority to EP02795892A priority patent/EP1458694A4/en
Priority to AU2002360620A priority patent/AU2002360620A1/en
Publication of WO2003053352A2 publication Critical patent/WO2003053352A2/en
Publication of WO2003053352A3 publication Critical patent/WO2003053352A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to novel LXR ligands of Formula (I) and the pharmaceutically acceptable salts and esters thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
PCT/US2002/040236 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions Ceased WO2003053352A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003554112A JP2005519042A (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions
US10/498,771 US20040266849A1 (en) 2002-12-16 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions
CA002470591A CA2470591A1 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions
EP02795892A EP1458694A4 (en) 2001-12-20 2002-12-16 THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIC CONDITIONS
AU2002360620A AU2002360620A1 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34255601P 2001-12-20 2001-12-20
US60/342,556 2001-12-20

Publications (2)

Publication Number Publication Date
WO2003053352A2 WO2003053352A2 (en) 2003-07-03
WO2003053352A3 true WO2003053352A3 (en) 2003-11-20

Family

ID=23342338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040236 Ceased WO2003053352A2 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions

Country Status (5)

Country Link
EP (1) EP1458694A4 (en)
JP (1) JP2005519042A (en)
AU (1) AU2002360620A1 (en)
CA (1) CA2470591A1 (en)
WO (1) WO2003053352A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569602B2 (en) 2003-10-16 2009-08-04 Asterand Uk Limited Furan derivatives as EP4 receptor antagonists

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2392568A1 (en) * 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
US7125865B2 (en) 2002-07-25 2006-10-24 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
CA2585623C (en) 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Ortho-substituted benzene derivatives
KR20070086194A (en) * 2004-12-14 2007-08-27 사노피-아벤티스 도이칠란트 게엠베하 Use of substituted cyclopropanoic acid derivatives for the manufacture of a medicament for the treatment of metabolic syndrome
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR101901741B1 (en) 2010-09-07 2018-10-01 서울대학교산학협력단 Sesterterpene compounds and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028137A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028137A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] XP002964553, accession no. STN Database accession no. 1997:533628 *
See also references of EP1458694A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569602B2 (en) 2003-10-16 2009-08-04 Asterand Uk Limited Furan derivatives as EP4 receptor antagonists

Also Published As

Publication number Publication date
JP2005519042A (en) 2005-06-30
AU2002360620A1 (en) 2003-07-09
WO2003053352A2 (en) 2003-07-03
EP1458694A4 (en) 2005-12-14
CA2470591A1 (en) 2003-07-03
EP1458694A2 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
JO2282B1 (en) Oxazol derivatives
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MXPA03011515A (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents.
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
WO2005030120A3 (en) Antiangiogenic agents
WO2005021497A3 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
GB0130677D0 (en) Medicaments and novel compounds
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2002079149A3 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2002096420A3 (en) Method for treating nerve injury caused by surgery
AU2003288231A8 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
WO2003051838A3 (en) Protein kinase inhibitors
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
BG105953A (en) METHOD FOR TREATMENT OF CHRONIC OBSTRUCTIVE BENEFITAL DISEASE
WO2002096855A3 (en) Anticholinergic compounds and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10498771

Country of ref document: US

Ref document number: 2470591

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002795892

Country of ref document: EP

Ref document number: 2003554112

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002360620

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002795892

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002795892

Country of ref document: EP